DPP-4 Inhibitors - Cardiovascular Outcomes - Regner Health Solutions

DPP-4 inhibitors, a class of medications primarily used in the management of type 2 diabetes, have garnered increasing attention in recent years due to their potential impact on cardiovascular outcomes. While initially developed for their glucose-lowering effects, studies have explored the cardiovascular effects of DPP-4 inhibitors in individuals with diabetes, particularly regarding the prevention of cardiovascular events such as heart attacks and strokes. One notable study, the SAVOR-TIMI 53 trial, found that the DPP-4 inhibitor saxagliptin did not significantly increase or decrease the risk of cardiovascular events, such as heart attack or stroke, compared to placebo. However, there was a slight increase in the risk of hospitalization for heart failure. On the other hand, the EXAMINE trial demonstrated a neutral effect of another DPP-4 inhibitor called alogliptin on cardiovascular outcomes. No significant differences were observed between alogliptin and placebo regarding major cardiovascular events or hospitalization for heart failure. Beyond the effects on the incretin system, DPP-4 inhibitors may directly impact the heart and cardiovascular risk factors. Preclinical studies suggest that DPP-4 inhibitors may improve cardiac function, reduce oxidative stress, and attenuate inflammation. Furthermore, these medications have been shown to decrease blood pressure and improve lipid profiles. Learn more about DPP-4 inhibitors and other services we offer: regnerhealthsolutions.com/dpp4-inhibitors/

from Flickr https://flic.kr/p/2pL92LW
via https://regnerhealthsolutions.com/